American biotechnology company at Bothell near Seattle in Washington, founded in 1997 and known for antibody drug conjugates, medicines that carry a cytotoxic payload to cancer cells with an antibody. Developed brentuximab vedotin for lymphoma, enfortumab vedotin for bladder cancer and tisotumab vedotin for cervical cancer, licensed its conjugation technology widely, and was bought by Pfizer for about forty three billion dollars in 2023.
No hay comentarios disponibles.
Deja tu valoración & comentario